Finance & valuation

Latest content

Chinese EV makers get serious about patents

Startups that have listed in the US and China look more like Tesla than Nikola from an IP portfolio perspective

24 September 2020

Confronting critical challenges, Taiwan’s tech companies must find a way to create patent value

IAM speaks with IP leaders from Foxconn, AU Optronics and others ahead of IPBC Taiwan next week

15 September 2020

Top IP owners in telecoms and semiconductors enjoy ongoing share advance

The latest numbers from the US Patent Elite index show stock price rises in both sectors continued into July

11 September 2020

Portfolio analysis shows BlackBerry’s new director of licensing has a lot to work with

The Canadian tech giant’s patents pack a punch and claims of a technologically diverse holding ring true, but slowing filing levels leave pipeline questions

11 September 2020

New licensing entity picks up portfolios from Samsung, Kyocera and TCL

Japan-based LLC’s first monetisation move is a licensor spot in Via’s LTE pool

11 September 2020

Pharma patent deal-making may be back with a bang

Following a spate of licensing deals, high-value life sciences M&A now seems to be back in business after a pandemic-induced pause

10 September 2020

The top 10 takeaways from this year’s Global Innovation Index

The latest edition of the annual WIPO publication reveals that Europe and North America still lead despite rising innovation levels in Asia

09 September 2020

Geely to boost R&D war chest with Shanghai listing

China’s next big IPO will feature one of the country’s auto IP leaders, which has more than 9,000 patents and counts licensing as a major revenue source

07 September 2020

Sanofi eyes more M&A as deals drive increase in IP portfolio quality

The French pharmaceutical’s holdings have shrunk over recent years and application output is at a low, but recent acquisitions have provided a boost while a patent revamp is around the corner

28 August 2020

Translational research key to realising value of university IP, says UCL biopharma chief

Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets

27 August 2020

Unlock unlimited access to all IAM content